VectivBio

Biotech & Life Sciences · Basel, Switzerland · Founded 2019 · IPO 2021

VectivBio is a biotechnology company dedicated to developing transformative therapies for severe rare diseases. Headquartered in Basel, Switzerland, with business operations in the New York area, VectivBio focuses on identifying and developing treatments for conditions with well-defined biology that can be targeted with tailored therapies. The company serves patients suffering from severe rare diseases, such as Short Bowel Syndrome with Intestinal Failure (SBS-IF), a rare and debilitating condition. VectivBio operates in the global biopharmaceutical market, leveraging its expertise in bioprocess development and rare disease drug development to create innovative solutions. The business model revolves around research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through the successful launch and lifecycle management of biotech and small molecule products. The company's patient-centric approach ensures that the needs and experiences of patients are at the forefront of its mission to improve lives. Keywords: biotechnology, rare diseases, patient-centric, transformative therapies, biopharmaceutical, SBS-IF, Basel, New York, drug development, innovative solutions.

Valuation $1.00B

Revenue $27M

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier Colt$25–100M revenue

Investors

13 investors on VectivBio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 11 investors entered at this stage

Novo Holdings

Pfizer

OrbiMed

Versant Ventures

Eventide Asset Management

Cormorant Capital

Bpifrance

Tekla Capital Management

Citadel

Cowen Group

Inserm Transfert Initiative

Series B+ 2 investors entered at this stage

Kreos Capital

Forbion Capital Partners

Global footprint

Where VectivBio has talent and traffic

Workforce by country

🇨🇭 Switzerland · Basel HQ

Book a demo for the full country breakdown

Talent graph

The shape of VectivBio's talent

Dealroom maps VectivBio's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

11 team members profilednamed & role-tagged by Dealroom

43 employeestotal headcount

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock VectivBio's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$5M patent portfolio · 8 active families

Estimated portfolio value

$5M

0.51% of market cap · 31× smaller than top peer Aurinia Pharmaceuticals ($159M)

8 active patent families

Where VectivBio innovates Medicinal chemistryPharmacologyCombinatorial chemistryOrganic chemistryPerylene derivatives

Where VectivBio concentrates vs peers

Each axis is a top-10 topic across VectivBio and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about VectivBio

An AI-synthesized read of the highest-engagement posts about VectivBio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See VectivBio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles